German biopharmaceutical company Formycon has postponed its annual meeting due to the coronavirus disease 2019 (COVID-19) pandemic.
German biosimilar development company Formycon has pushed back its annual meeting until December, a 5-month delay, owing to the coronavirus disease 2019 (COVID-19) pandemic.
Formycon is following the large-scale events ban directed by the German federal government in mid-April that will last through the end of August.
The company said the postponement will not affect the publication of its financial statement for the 2019 fiscal year, which will still be published as planned on May 18, 2020. Formycon generated roughly $29 million in sales and other earnings for the first 9 months of 2019; the company incurred a net operating income loss of roughly $7.5 million.
Formycon’s Biosimilar Pipeline
Formycon currently has 4 biosimilar products in its pipeline.
Its ranibizumab product (FYB201), referencing Lucentis and in partnership with Bioeq AG, is the furthest along after completing a phase 3 clinical trial. In February, the FDA requested additional data for the company’s Biologics License Application for FYB201.
Formycon’s ustekinumab biosimilar (FYB202), referencing Stelara, is being tested in a phase 1 clinical trial, and its aflibercept biosimilar (FYB203), referencing Eylea, is still in preclinical trials. FYB202 and FYB203 were licensed from Aristo Pharma GmbH and Santo Holding (Deutschland) GmbH, respectively.
FYB205 has no published results yet but was described by Formycon as “an early stage biosimilar project that has been progressed up to the initial cell line screening.”
“Each of these is positioned to potentially compete against existing blockbuster biopharmaceuticals, each with sales in the billions of dollars. The market potential for our product candidates is thus substantial,” said Formycon officials.
Formycon’s COVID-19 Involvement
In April, Formycon announced that it would start to develop COVID-19 biologic drugs using its antibody-based protein drug technology platform, computer-aided structural protein design, and screening tests for SARS-CoV-2 blocking antibody-based drugs.
“We are pleased to be able to contribute with Formycon, because antibody-based drugs have great potential as an important treatment option for COVID-19, and the long half-life of these large molecules could ultimately also protect physicians and care givers from infection in an outbreak scenario,” said Carsten Brockmeyer, PhD, chief executive officer of Formycon.
Patient Perceptions of Switching From the Reference Adalimumab to Amjevita During Its Initial Launch
April 20th 2024In a survey of patients with autoimmune arthritis who had been switched from reference adalimumab (Humira) to biosimilar adalimumab-atto (Amjevita; Amgen), most reported preferring the biosimilar and had no concerns about switching.
Decoding the Patent Puzzle: Navigating the Legal Landscape of Biosimilars
March 17th 2024On this episode of Not So Different, Ha Kung Wong, JD, an intellectual patent attorney and partner at Venable LLP, details the confusing landscape that is the US patent system and how it can be improved to help companies overcome barriers to biosimilar competition.
Biosimilars Rheumatology Roundup for February 2024—Podcast Edition
March 3rd 2024On this episode of Not So Different, The Center for Biosimilars® revisited all the major rheumatology biosimilar news from February 2024, including the FDA approval of the 10th adalimumab biosimilar, the promise for an oral delivery system for ustekinumab, and the impact of adalimumab products on COVID-19 antibodies.
Global Biosimilar Market Projected to Reach $1.3 Trillion by 2032
April 11th 2024The global biosimilar market is projected to surge from $25.1 billion in 2022 to approximately $1.3 trillion by 2032, with a compound annual growth rate of 17.6%, driven mainly by the increasing prevalence of cancer and the cost-effectiveness of biosimilars, as outlined in a report by Towards Healthcare.
Biosimilars Council: PBM Rebate Schemes Cost Americans, Payers $6 Billion
April 10th 2024A report from the Biosimilars Council evaluating IQVIA data found that rebate schemes orchestrated by pharmacy benefit managers (PBMs) are costing US patients and payers billions of dollars by suppressing biosimilar adoption.